TARA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TARA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Protara Therapeutics's other current liabilities for the quarter that ended in Sep. 2024 was $1.52 Mil.
Protara Therapeutics's quarterly other current liabilities declined from Mar. 2024 ($1.07 Mil) to Jun. 2024 ($1.00 Mil) but then increased from Jun. 2024 ($1.00 Mil) to Sep. 2024 ($1.52 Mil).
Protara Therapeutics's annual other current liabilities increased from Dec. 2021 ($1.80 Mil) to Dec. 2022 ($2.54 Mil) but then declined from Dec. 2022 ($2.54 Mil) to Dec. 2023 ($2.11 Mil).
The historical data trend for Protara Therapeutics's Other Current Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protara Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Current Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
Protara Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Other Current Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.
Thank you for viewing the detailed overview of Protara Therapeutics's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Opaleye Management Inc. | 10 percent owner | ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
Patrick Fabbio | officer: Chief Financial Officer | 2 PITNEY COURT, BASKING RIDGE NJ 07920 |
Jesse Shefferman | director, officer: CEO and President | C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Hannah Fry | officer: VP, Controller | 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010 |
Luke M Beshar | director | 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921 |
Jathin Bandari | officer: Chief Medical Officer | C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010 |
Jane Huang | director | C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108 |
Martin Sebastian Olivo | officer: Chief Medical Officer | C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Blaine Davis | officer: Chief Financial Officer | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Randall Marshall | 10 percent owner | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Barry P Flannelly | director | ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880 |
Richard S Levy | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julio Casoy | officer: Chief Medical Officer | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
Jacqueline Zummo | officer: Sr. Vice President, Research | C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014 |
From GuruFocus
By Marketwired • 08-06-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 09-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 09-03-2024
By Marketwired • 12-03-2024
By Marketwired • 12-05-2024
By Marketwired • 11-03-2023
By GuruFocus Research • 09-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.